Decoy Therapeutics Inc's Business Segments

Decoy Therapeutics Inc., formerly Salarius Pharmaceuticals, is a preclinical biotechnology company developing peptide conjugate therapeutics using its proprietary IMP 3 ACT™ platform. This platform employs machine learning, artificial intelligence, and high-speed synthesis to engineer and manufacture peptide conjugates targeting infectious diseases and oncology. The company has no approved products or revenue from sales. In November 2025, Decoy completed a merger with Legacy Decoy, combining drug development approaches and expanding its pipeline to include Designable Multi-Antivirals (D-MAV) candidates for respiratory viruses. Legacy Salarius clinical candidates include two small molecule drugs addressing gene dysregulation: SP-3164, a targeted protein degrader, and seclidemstat (SP-2577), a targeted protein inhibitor. Decoy supported a clinical trial of SP-2577 at The University of Texas MD Anderson Cancer Center but plans to seek strategic alternatives for this program. The merger integrates peptide conjugates with small molecule assets to address a broader range of diseases and undruggable targets. Decoy Therapeutics’ common stock trades on Nasdaq under the symbol "DCOY."

The Company operates in a single operating segment, concentrating on the discovery and development of therapeutics for patients with significant unmet medical needs. It also operates within one geographic segment.